Molica, S.; Shanafelt, T.D.; Allsup, D.; Giannarelli, D.
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers 2024, 16, 1085.
https://doi.org/10.3390/cancers16061085
AMA Style
Molica S, Shanafelt TD, Allsup D, Giannarelli D.
Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers. 2024; 16(6):1085.
https://doi.org/10.3390/cancers16061085
Chicago/Turabian Style
Molica, Stefano, Tait D. Shanafelt, David Allsup, and Diana Giannarelli.
2024. "Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population" Cancers 16, no. 6: 1085.
https://doi.org/10.3390/cancers16061085
APA Style
Molica, S., Shanafelt, T. D., Allsup, D., & Giannarelli, D.
(2024). Impact of Targeted Agents on Survival of Chronic Lymphocytic Leukemia Patients Fit for Fludarabine, Cyclophosphamide, and Rituximab (FCR) Relative to Age- and Sex-Matched Population. Cancers, 16(6), 1085.
https://doi.org/10.3390/cancers16061085